Exhibit 10.24 AMENDMENT NO. 1 TO EXCLUSIVE SUBLICENSE AGREEMENT This Amendment No. 1 is made to the Exclusive Sublicense Agreement made December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals, Inc., a New York corporation...

                                                                   Exhibit 10.24

                AMENDMENT NO. 1 TO EXCLUSIVE SUBLICENSE AGREEMENT

      This Amendment No. 1 is made to the Exclusive Sublicense Agreement made
December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals,
Inc., a New York corporation ("Luitpold") and BioMimetic Therapeutics,
Inc.(formerly BioMimetic Pharmaceuticals, Inc.), a Delaware corporation ("BMTI")
(each, individually a "Party" and collectively, the "Parties") as of this 21th
day of December, 2005.

      WHEREAS, the Term of the Agreement was to extend to December 31, 2014, or
until the last to expire valid patent claim in a country; and

      WHEREAS, the Parties have agreed to extend the Term of the Agreement;

      NOW, THEREFORE, in consideration of the mutual premises, covenants, and
agreements hereinafter set forth, the sufficiency of which is hereby
acknowledged, the Parties to the Agreement, intending to be bound, mutually
agree as follows:

      1.    Section 3.1 of the Agreement is amended as follows:

            "The term of this Agreement shall be for a period beginning on the
            Effective Date and shall continue until December 31, 2026. By no
            later than December 31, 2025, Luitpold shall have the right to
            extend the term of this Agreement for a period of five (5) years by
            notice to BMTI and thereafter it shall have the right to extend the
            term for additional five (5) year terms upon one (1) year's notice
            to BMTI. If extended, Section 4.3, among other provisions, survives
            for so long as Luitpold relies upon Know-how, trademarks, trade
            secrets and/or other proprietary technology or information developed
            by BMPI."

      2.    Except as otherwise expressly amended above, all provisions of the
Agreement shall continue to remain in full force and effect.




      IN WITNESS WHEREOF, Luitpold and BMTI have entered into this Amendment No.
1 effective as of the date hereinabove written, each by a duly authorized
officer, in duplicate originals.

LUITPOLD PHARMACEUTICALS, INC.                  BIOMIMETIC THERAPEUTICS, INC.


By:/s/ Xxxx Xxxx Xxxxxxx                        By:/s/ Xxxxxx Xxxxx
   ------------------------------------------      -------------------------
       Xxxx Xxxx Xxxxxxx, R. Ph., M.S., M.B.A.         Xxxxxx Xxxxx, D.D.S.
       President abd CEO                               President and CEO


                                      - 2 -